{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:09:37Z","timestamp":1790345377314,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12325-024-02956-0","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T09:02:22Z","timestamp":1723885342000},"page":"3888-3904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical and Humanistic Burden of Non-inhibitor Haemophilia\u00a0A in Five European Countries: Insights from the CHESS\u00a0II Study"],"prefix":"10.1007","volume":"41","author":[{"given":"Enrico","family":"Ferri Grazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetan","family":"Duport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel-Anibal","family":"Garcia Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5716-0748","authenticated-orcid":false,"given":"Tom","family":"Blenkiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"2956_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","volume":"344","author":"P Mannucci","year":"2001","unstructured":"Mannucci P, Tuddenham E. The hemophilias\u2014from royal genes to gene therapy. N Engl J Med. 2001;344:1773\u20139.","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"2956_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"8","key":"2956_CR3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/jth.12317","volume":"11","author":"M Escobar","year":"2013","unstructured":"Escobar M, Sallah S. Hemophilia\u00a0A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis. J Thromb Haemost. 2013;11(8):1449\u201353.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2956_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","volume":"16","author":"J O\u2019Hara","year":"2018","unstructured":"O\u2019Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2956_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/hae.14171","volume":"27","author":"S O\u2019Hara","year":"2021","unstructured":"O\u2019Hara S, Castro FA, Black J, et al. Disease burden and remaining unmet need in patients with haemophilia\u00a0A treated with primary prophylaxis. Haemophilia. 2021;27(1):113\u20139.","journal-title":"Haemophilia"},{"issue":"6","key":"2956_CR6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/hae.14302","volume":"27","author":"J O\u2019Hara","year":"2021","unstructured":"O\u2019Hara J, Noone D, Jain M, et al. Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia\u00a0A. Haemophilia. 2021;27(6):938\u201346.","journal-title":"Haemophilia"},{"key":"2956_CR7","volume-title":"Impact of hemophilia on employment - Insights from the PROBE Study","author":"A Pastarnak","year":"2018","unstructured":"Pastarnak A, O\u2019Mahony B, Chai-Adisaksopha C, et al. Impact of hemophilia on employment - Insights from the PROBE Study. National Hemophilia Foundation; 2018."},{"issue":"5","key":"2956_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1538-7836.2009.03318.x","volume":"7","author":"SM Siboni","year":"2009","unstructured":"Siboni SM, Mannucci PM, Gringeri A, et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost JTH. 2009;7(5):780\u20136.","journal-title":"J Thromb Haemost JTH"},{"issue":"1","key":"2956_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","volume":"12","author":"J O\u2019Hara","year":"2017","unstructured":"O\u2019Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Diseas. 2017;12(1):106.","journal-title":"Orphanet J Rare Diseas"},{"issue":"1","key":"2956_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/hae.13111","volume":"23","author":"E Berntorp","year":"2017","unstructured":"Berntorp E, Dolan G, Hay C, et al. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017;23(1):105\u201314.","journal-title":"Haemophilia"},{"issue":"17","key":"2956_CR11","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","volume":"129","author":"MJ Manco-Johnson","year":"2017","unstructured":"Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368\u201374.","journal-title":"Blood"},{"issue":"3","key":"2956_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/13543784.2020.1723547","volume":"29","author":"PM Mannucci","year":"2020","unstructured":"Mannucci PM. Benefits and limitations of extended plasma half-life factor\u00a0VIII products in hemophilia\u00a0A. Expert Opin Investig Drugs. 2020;29(3):303\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"2956_CR13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/jth.14784","volume":"18","author":"F Peyvandi","year":"2020","unstructured":"Peyvandi F, Kenet G, Pekrul I, et al. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost. 2020;18(6):1242\u201355.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2956_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.hoc.2017.06.011","volume":"31","author":"AC Nathwani","year":"2017","unstructured":"Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol Oncol Clin N Am. 2017;31(5):853\u201368.","journal-title":"Hematol Oncol Clin N Am"},{"key":"2956_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/JBM.S363028","volume":"13","author":"E Ferri Grazzi","year":"2022","unstructured":"Ferri Grazzi E, Sun SX, Burke T, et al. The impact of pharmacokinetic-guided prophylaxis on clinical outcomes and healthcare resource utilization in hemophilia a patients: real-world evidence from the CHESS\u00a0II Study. JBM. 2022;13:505\u201316.","journal-title":"JBM"},{"key":"2956_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s13023-021-02152-1","volume":"16","author":"T Burke","year":"2020","unstructured":"Burke T, Asghar S, O\u2019hara J, et al. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS\u00a0II real-world burden of illness study in Europe. Orphanet J Rare Dis. 2020;16:521.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"2956_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. Jo Thromb Haemost. 2014;12(11):1935\u20139.","journal-title":"Jo Thromb Haemost"},{"issue":"1","key":"2956_CR18","first-page":"608","volume":"12","author":"T Burke","year":"2022","unstructured":"Burke T, Rodriguez-Santana I, Chowdary P, et al. Humanistic burden of problem joints for children and adults with haemophilia. Haemophilia. 2022;12(1):608\u2013618.","journal-title":"Haemophilia"},{"issue":"3 Suppl 2","key":"2956_CR19","first-page":"3","volume":"30","author":"MS Gilbert","year":"1993","unstructured":"Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol. 1993;30(3 Suppl 2):3\u20136.","journal-title":"Semin Hematol"},{"issue":"10","key":"2956_CR20","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"5","key":"2956_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2956_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, et al. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205\u201316.","journal-title":"Eur J Health Econ"},{"key":"2956_CR23","doi-asserted-by":"publisher","first-page":"S685","DOI":"10.1016\/j.jval.2020.08.1705","volume":"23","author":"J Azzi","year":"2020","unstructured":"Azzi J, Gautier L, Saba G, et al. PNS261 EQ-5D-5L in France, Germany and Spain: population norms and comparison between the countries. Value Health. 2020;23:S685.","journal-title":"Value Health"},{"issue":"3","key":"2956_CR24","first-page":"e11457-1","volume":"12","author":"L Scalone","year":"2015","unstructured":"Scalone L, Cortesi PA, Ciampichini R, et al. Health related quality of life norm data of the general population in Italy: results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol Biostat Public Health. 2015;12(3):e11457-1\u2013e11457-15.","journal-title":"Epidemiol Biostat Public Health"},{"issue":"6","key":"2956_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10198-019-01054-1","volume":"20","author":"T Grochtdreis","year":"2019","unstructured":"Grochtdreis T, Dams J, K\u00f6nig HH, et al. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20(6):933\u201344.","journal-title":"Eur J Health Econ"},{"key":"2956_CR26","doi-asserted-by":"crossref","unstructured":"Hernandez G, Garin O, Pardo Y, et al. Validity of the EQ-5D-5L and reference norms for the Spanish population. Qual Life Res. 2018;27(9):2337\u201348.","DOI":"10.1007\/s11136-018-1877-5"},{"issue":"6","key":"2956_CR27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/rth2.12347","volume":"4","author":"M Wang","year":"2020","unstructured":"Wang M, Recht M, Iyer NN, et al. Hemophilia without prophylaxis: assessment of joint range of motion and factor activity. Res Pract Thromb Haemost. 2020;4(6):1035\u201345.","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2956_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pain.2009.06.004","volume":"145","author":"J Elander","year":"2009","unstructured":"Elander J, Robinson G, Mitchell K, et al. An assessment of the relative influence of pain coping, negative thoughts about pain, and pain acceptance on health-related quality of life among people with hemophilia. Pain. 2009;145(1):169\u201375.","journal-title":"Pain"},{"issue":"5","key":"2956_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2516.2012.02808.x","volume":"18","author":"K Holstein","year":"2012","unstructured":"Holstein K, Klamroth R, Richards M, et al. Pain management in patients with haemophilia: a European survey. Haemophilia. 2012;18(5):743\u201352.","journal-title":"Haemophilia"},{"issue":"2","key":"2956_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/hae.14278","volume":"27","author":"J O\u2019Hara","year":"2021","unstructured":"O\u2019Hara J, Martin AP, Nugent D, et al. Evidence of a disability paradox in patient-reported outcomes in haemophilia. Haemophilia. 2021;27(2):245\u201352.","journal-title":"Haemophilia"},{"issue":"3","key":"2956_CR31","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1111\/hae.13698","volume":"25","author":"PF Limperg","year":"2019","unstructured":"Limperg PF, Maurice-Stam H, Haverman L, et al. Professional functioning of young adults with congenital coagulation disorders in the Netherlands. Haemophilia. 2019;25(3):e138\u201345.","journal-title":"Haemophilia"},{"issue":"3","key":"2956_CR32","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1016\/j.jval.2015.03.148","volume":"18","author":"N Tundia","year":"2015","unstructured":"Tundia N, Hass S, Fuldeore M, et al. Validation and US population norms of health-related productivity questionnaire. Value Health. 2015;18(3):A24.","journal-title":"Value Health"},{"key":"2956_CR33","volume-title":"Report on the Annual Global Survey 2020","author":"World Federation of Hemophilia","year":"2021","unstructured":"World Federation of Hemophilia. Report on the Annual Global Survey 2020. Montreal: WFH; 2021."},{"issue":"1","key":"2956_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02300-1","volume":"17","author":"I Rodriguez-Santana","year":"2022","unstructured":"Rodriguez-Santana I, DasMahapatra P, Burke T, et al. Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS\u00a0II study. Orphanet J Rare Dis. 2022;17(1):1\u201310.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2956_CR35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/hae.13777","volume":"25","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi F, Tavakkoli F, Frame D, et al. Burden of mild haemophilia\u00a0A: systematic literature review. Haemophilia. 2019;25(5):755\u201363.","journal-title":"Haemophilia"},{"key":"2956_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1182\/asheducation-2010.1.191","volume":"2010","author":"C Philipp","year":"2010","unstructured":"Philipp C. The aging patient with hemophilia: complications, comorbidities, and management issues. Hematology Am Soc Hematol Educ Program. 2010;2010:191\u20136.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2956_CR37","first-page":"722","volume":"86","author":"S Trippoli","year":"2001","unstructured":"Trippoli S, Vaiani M, Linari S, et al. Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia. Haematologica. 2001;86(7):722\u20138.","journal-title":"Haematologica"},{"issue":"2","key":"2956_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. Pharmacoeconomics. 2023;41(2):199\u2013207.","journal-title":"Pharmacoeconomics"},{"key":"2956_CR39","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022;(January):1\u2013181."},{"key":"2956_CR40","doi-asserted-by":"crossref","unstructured":"DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Int Med 2022;175(9):1298\u2013304","DOI":"10.7326\/M22-1460"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02956-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02956-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02956-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:25:33Z","timestamp":1726244733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02956-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2956"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02956-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Enrico Ferri Grazzi, Tom Blenkiron, Jamie O\u2019Hara and Tom Burke are employees of HCD Economics Ltd., a consultancy which received research funding from BioMarin Europe; Charlotte Camp and Charles Hawes are employees and stockholders of BioMarin Pharmaceutical, Inc. Tobias Becker, Stephanie Brandt, Gaetan Duport, Daniel-Anibal Garcia Diego, Angelo Lupi, William McKeown and Debra Morgan have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The CHESS\u00a0II study was approved by the Research Ethics committee of the Faculty of Health and Social Care within the University of Chester (UK) and was conducted in accordance with regional and relevant guidelines. The study was conducted in collaboration with the UK Haemophilia Society and governed by a steering committee chaired by Mr Brian O\u2019Mahony, Chief Executive of the Irish Haemophilia Society.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}